Abstract
Calcium antagonists such as diltiazem may play a promising role in reducing ischaemia during percutaneous transluminal coronary angioplasty (PTCA) and in preventing cardiac events in patients with unstable angina. An ongoing study, the Incomplete INfarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis/Tildiem® (INTERCEPT), also aims to investigate whether prophylactic administration of diltiazem and aspirin can reduce the incidence of ischaemic complications in patients with a first acute myocardial infarction (MI) who are receiving thrombolytic therapy. These and other data were presented at a satellite symposium sponsored by Synthelabo, which was held at the XVIIth Congress of the European Society of Cardiology [Amsterdam, The Netherlands; August 1995].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
